Anwen Liu

机构：Nanchang University, First Affiliated Hospital of Jiangxi Medical College, Second Affiliated Hospital of Nanchang University · ORCID：0000-0001-5279-1068

发表论文 147 篇 · 总被引 2325 次 · h-index 24

代表论文

• First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial (2025 · Nature Medicine · 被引 20)
• Mediation of macrophage M1 polarization dynamics change by ubiquitin-autophagy-pathway regulated NLRP3 inflammasomes in PD-1 inhibitor-related myocardial inflammatory injury (2025 · Inflammation Research · 被引 19)
• Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B) (2025 · Journal of Clinical Oncology · 被引 17)
• Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study (2025 · Cancer Immunology Immunotherapy · 被引 13)
• Integrated multi-omics reveals glycolytic gene signatures of lung adenocarcinoma brain metastasis and the impact of Rac2 lactylation on immunosuppressive microenvironment (2025 · Journal of Translational Medicine · 被引 9)
• Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancers (2025 · Med · 被引 9)